Malvern, PA - YPrime announces the release of its data-driven electronic clinical outcome assessment (eCOA) technology platform. Designed to capture endpoints from multiple modalities and streamline patient data collection in clinical trials, YPrime's eCOA technology supports sponsors, sites and patients while delivering consumer-friendly applications built on the best standards of user experience principles.
YPrime's eCOA solutions offer data capture in virtually any clinical research setting, with features that promote user convenience, compliance and data integrity:
"YPrime's approach to eCOA is a great example of our collective efforts to uncomplicate patient data collection," said Shawn Blackburn, CEO and co-founder. "This platform, which offers the most advanced features in the marketplace, provides the tools that make clinical endpoint collection quicker, easier and considerably less frustrating. Technology that focuses on the end user's experience, particularly for site and patients will have a landmark effect on the way we conduct clinical trials in the future."
About YPrime
YPrime offers more than a decade of focused work with eclinical systems to expedite and improve the quality of patient management, clinical supplies, drug accountability and clinical data. Cloud-based interactive response technology (IRT) and electronic clinical outcome assessment (eCOA) platforms enable greater speed, precision and integration in clinical trial management. Our data services tools help sponsors bring together fragmented clinical research data into contextual information they can act on. YPrime's technology and service offerings enable sponsors to move faster and more efficiently to their next development milestone.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.